Abstract
As the GIT Market begins to feature increasingly high levels of generic
competition, the focus of pharmaceutical R&D strategies has shifted towards
new therapy areas such as Crohn' s disease and Irritable Bowel Syndrome (IBS).
Although such shifts are becoming the driving force for market transformation,
growth rates may remain low due to the increased availability of effective
generic medicines and fewer launches of innovative new drugs. ' The
Gastrointestinal Market Outlook to 2012' is a new report published by Business
Insights that provides a detailed epidemiological analysis of key indications
within major GIT markets, and examines the factors impacting their prevalence.
The dynamics of the market are examined through an analysis of leading brands
within each indication and a profile of the pharma companies and market trends
influencing the sales of GIT treatments. Forecasts for major product sales
over the 2006-12 period are also provided.
View Cart
